Re: Chokesuwattanaskul et al. Safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: Meta‐analysis

Rifkin, Dena E.

doi:10.1111/pace.13394

Cited by 3 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…при ФП и ХБП Антагонист витамина К варфарин исторически был краеугольным камнем антикоагулянтной терапии пациентов с ХБП [13]. Он продемонстрировал благоприятные эффекты, снижая смертность в данной категории пациентов [14,15].…”

Section: в поиске лучшего антикоагулянтаunclassified

“…К сожалению, РКИ у пациентов с ФП и СКФ <30 мл/мин/1,73 м 2 не проводилось, поэтому срав-нивать ПОАК и варфарин в данной категории пациентов можно только в обсервационных исследованиях, метаанализах и регистрах. В метаанализ Chokesuwattanaskul R, et al [13] были включены 5 крупных исследований с общим количеством пациентов 43850 с ТБП. Были показаны значительное снижение риска кровотечений при приёме ПОАК (отношение шансов (ОШ) 0,42; 95% ДИ 0,28-0,6) по сравнению с варфарином и недостоверные различия в профилактике тромбоэмболий (ОШ 0,56; 95% ДИ 0,23-1,39).…”

Section: антикоагуляция при тбп (Iv и V стадии хбп)unclassified

“…Однако в европейских рекомендациях и аннотации апиксабана указывается IV стадия ХБП. Не случайно в метаанализах Chokesuwattanaskul R, et al [13] и Godino C, et al [28] апиксабан был наиболее часто используемым ПОАК при всех стадиях ХБП, что отражает доверие врачей и пациентов к выбору ПОАК при данном сочетании болезней.…”

Section: антикоагуляция при тбп (Iv и V стадии хбп)unclassified

See 2 more Smart Citations

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Загидуллин

Davtyan

2021

Russ J Cardiol

View full text Add to dashboard Cite

Due to the population aging and the accumulation of concomitant diseases, the prevalence of atrial fibrillation (AF) as the most common arrhythmia is increasing. On the other hand, 14% of the population has chronic kidney disease (CKD). These conditions are often combined with each other causing a prothrombogenic effect, which significantly increase the number of unfavorable outcomes such as thromboembolism, stroke, myocardial infarction and cardiovascular death. This is especially true for the last stages of CKD, the so-called end-stage renal disease with a glomerular filtration rate <29 ml/min/1,73 m2. Previously, the vitamin K antagonist warfarin was the central drug for anticoagulant therapy of AF + CKD combination, but in the last decade, direct oral anticoagulants became widely used. This article discusses the evidence base for using each of the anticoagulants in patients with AF+CKD combination compared with warfarin, including depending on the severity of glomerular filtration rate decrease.

show abstract

Section: в поиске лучшего антикоагулянтаunclassified

Section: антикоагуляция при тбп (Iv и V стадии хбп)unclassified

See 1 more Smart Citation

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Загидуллин

Davtyan

2021

Russ J Cardiol

View full text Add to dashboard Cite

show abstract

“…2 Historically, warfarin has been the cornerstone of therapy for patients requiring anticoagulation with stage 4 and 5 CKD. 3 The Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE) study demonstrated that apixaban is superior to warfarin in prevention of stroke in patients with AF with less bleeding compared to warfarin. 4 The Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY) study exhibited similar results regarding bleeding.…”

Section: Introductionmentioning

confidence: 99%

Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital

et al. 2019

View full text Add to dashboard Cite

Background: Warfarin has been the cornerstone of therapy for patients with stage 4 and 5 chronic kidney disease (CKD) requiring anticoagulation. These patients were omitted from landmark clinical trials involving apixaban. Apixaban’s safety profile is still largely unclear in this population. Objectives: To compare major bleeding, secondary bleeding outcomes, stroke, and thromboembolism in veterans with CKD stage 4, with CKD stage 5, and on dialysis on apixaban or warfarin. Methods: A retrospective chart review identified veterans with CKD stage 4 and stage 5, and on dialysis who received either apixaban or warfarin from 2013 to 2019 at the Memphis Veterans Affairs Medical Center. The primary outcome was incidence of major bleeding. Secondary outcomes were clinically relevant nonmajor and minor bleeding, composite bleeding, venous thromboembolism (VTE), and stroke. Results: A total of 111 patients were included in this study (warfarin group, n = 57; apixaban group, n = 54). Primary and secondary outcomes were analyzed using the χ2 or Fisher exact tests as appropriate. There was no difference in major bleeding between groups (14% vs 7%, P = 0.362). There were increased rates of minor bleeding (26% vs 6%, P = 0.004) and composite bleeding (46% vs 20%, P = 0.004) in patients receiving warfarin. There were no differences in rates of stroke or VTE between the 2 groups. Conclusion and Relevance: There was no difference in major bleeding in patients who received apixaban compared with warfarin. Apixaban may be a reasonable alternative to warfarin in veterans with CKD stage 4 and 5, including those on dialysis.

show abstract

Letter to the Editor: “Incidence of atrial fibrillation in pregnancy and clinical significance: A meta-analysis”

Ramlakhan

Roos‐Hesselink

2021

Advances in Medical Sciences

View full text Add to dashboard Cite

Re: Chokesuwattanaskul et al. Safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: Meta‐analysis

Cited by 3 publications

References 3 publications

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital

Letter to the Editor: “Incidence of atrial fibrillation in pregnancy and clinical significance: A meta-analysis”

Contact Info

Product

Resources

About